205 related articles for article (PubMed ID: 22006831)
21. Wheelchair use and lipophilic statin medications may influence bone loss in chronic spinal cord injury: findings from the FRASCI-bone loss study.
Morse LR; Nguyen N; Battaglino RA; Guarino AJ; Gagnon DR; Zafonte R; Garshick E
Osteoporos Int; 2016 Dec; 27(12):3503-3511. PubMed ID: 27412619
[TBL] [Abstract][Full Text] [Related]
22. Increased sclerostin serum levels associated with bone formation and resorption markers in patients with immobilization-induced bone loss.
Gaudio A; Pennisi P; Bratengeier C; Torrisi V; Lindner B; Mangiafico RA; Pulvirenti I; Hawa G; Tringali G; Fiore CE
J Clin Endocrinol Metab; 2010 May; 95(5):2248-53. PubMed ID: 20305005
[TBL] [Abstract][Full Text] [Related]
23. Sclerostin levels during growth in children.
Kirmani S; Amin S; McCready LK; Atkinson EJ; Melton LJ; Müller R; Khosla S
Osteoporos Int; 2012 Mar; 23(3):1123-30. PubMed ID: 21617991
[TBL] [Abstract][Full Text] [Related]
24. Sclerostin levels associated with inhibition of the Wnt/β-catenin signaling and reduced bone turnover in type 2 diabetes mellitus.
Gaudio A; Privitera F; Battaglia K; Torrisi V; Sidoti MH; Pulvirenti I; Canzonieri E; Tringali G; Fiore CE
J Clin Endocrinol Metab; 2012 Oct; 97(10):3744-50. PubMed ID: 22855334
[TBL] [Abstract][Full Text] [Related]
25. The Wnt Inhibitor Sclerostin Is Up-regulated by Mechanical Unloading in Osteocytes in Vitro.
Spatz JM; Wein MN; Gooi JH; Qu Y; Garr JL; Liu S; Barry KJ; Uda Y; Lai F; Dedic C; Balcells-Camps M; Kronenberg HM; Babij P; Pajevic PD
J Biol Chem; 2015 Jul; 290(27):16744-58. PubMed ID: 25953900
[TBL] [Abstract][Full Text] [Related]
26. Association of serum sclerostin with bone mineral density, bone turnover, steroid and parathyroid hormones, and fracture risk in postmenopausal women: the OFELY study.
Garnero P; Sornay-Rendu E; Munoz F; Borel O; Chapurlat RD
Osteoporos Int; 2013 Feb; 24(2):489-94. PubMed ID: 22525978
[TBL] [Abstract][Full Text] [Related]
27. Sclerostin and its association with physical activity, age, gender, body composition, and bone mineral content in healthy adults.
Amrein K; Amrein S; Drexler C; Dimai HP; Dobnig H; Pfeifer K; Tomaschitz A; Pieber TR; Fahrleitner-Pammer A
J Clin Endocrinol Metab; 2012 Jan; 97(1):148-54. PubMed ID: 21994959
[TBL] [Abstract][Full Text] [Related]
28. Effect of recent spinal cord injury on the OPG/RANKL system and its relationship with bone loss and the response to denosumab therapy.
Gifre L; Ruiz-Gaspà S; Carrasco JL; Portell E; Vidal J; Muxi A; Monegal A; Guañabens N; Peris P
Osteoporos Int; 2017 Sep; 28(9):2707-2715. PubMed ID: 28580511
[TBL] [Abstract][Full Text] [Related]
29. Serum extracellular secreted antagonists of the canonical Wnt/β-catenin signaling pathway in patients with Cushing's syndrome.
Belaya ZE; Rozhinskaya LY; Melnichenko GA; Solodovnikov AG; Dragunova NV; Iljin AV; Dzeranova LK; Dedov II
Osteoporos Int; 2013 Aug; 24(8):2191-9. PubMed ID: 23358608
[TBL] [Abstract][Full Text] [Related]
30. Adiponectin is associated with bone strength and fracture history in paralyzed men with spinal cord injury.
Tan CO; Battaglino RA; Doherty AL; Gupta R; Lazzari AA; Garshick E; Zafonte R; Morse LR
Osteoporos Int; 2014 Nov; 25(11):2599-607. PubMed ID: 24980185
[TBL] [Abstract][Full Text] [Related]
31. Serum sclerostin increases in healthy adult men during bed rest.
Spatz JM; Fields EE; Yu EW; Divieti Pajevic P; Bouxsein ML; Sibonga JD; Zwart SR; Smith SM
J Clin Endocrinol Metab; 2012 Sep; 97(9):E1736-40. PubMed ID: 22767636
[TBL] [Abstract][Full Text] [Related]
32. Effects of pharmacologic sclerostin inhibition or testosterone administration on soleus muscle atrophy in rodents after spinal cord injury.
Phillips EG; Beggs LA; Ye F; Conover CF; Beck DT; Otzel DM; Ghosh P; Bassit ACF; Borst SE; Yarrow JF
PLoS One; 2018; 13(3):e0194440. PubMed ID: 29579075
[TBL] [Abstract][Full Text] [Related]
33. Sclerostin blood levels before and after kidney transplantation.
Bonani M; Rodriguez D; Fehr T; Mohebbi N; Brockmann J; Blum M; Graf N; Frey D; Wüthrich RP
Kidney Blood Press Res; 2014; 39(4):230-9. PubMed ID: 25118597
[TBL] [Abstract][Full Text] [Related]
34. Bone biomarkers in patients with chronic traumatic spinal cord injury.
Sabour H; Norouzi Javidan A; Latifi S; Larijani B; Shidfar F; Vafa MR; Heshmat R; Emami Razavi H
Spine J; 2014 Jul; 14(7):1132-8. PubMed ID: 24139865
[TBL] [Abstract][Full Text] [Related]
35. Bone architecture adaptations after spinal cord injury: impact of long-term vibration of a constrained lower limb.
Dudley-Javoroski S; Petrie MA; McHenry CL; Amelon RE; Saha PK; Shields RK
Osteoporos Int; 2016 Mar; 27(3):1149-1160. PubMed ID: 26395887
[TBL] [Abstract][Full Text] [Related]
36. Relation of age, gender, and bone mass to circulating sclerostin levels in women and men.
Mödder UI; Hoey KA; Amin S; McCready LK; Achenbach SJ; Riggs BL; Melton LJ; Khosla S
J Bone Miner Res; 2011 Feb; 26(2):373-9. PubMed ID: 20721932
[TBL] [Abstract][Full Text] [Related]
37. Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin.
Robling AG; Niziolek PJ; Baldridge LA; Condon KW; Allen MR; Alam I; Mantila SM; Gluhak-Heinrich J; Bellido TM; Harris SE; Turner CH
J Biol Chem; 2008 Feb; 283(9):5866-75. PubMed ID: 18089564
[TBL] [Abstract][Full Text] [Related]
38. Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt/beta-catenin signaling.
Lin C; Jiang X; Dai Z; Guo X; Weng T; Wang J; Li Y; Feng G; Gao X; He L
J Bone Miner Res; 2009 Oct; 24(10):1651-61. PubMed ID: 19419300
[TBL] [Abstract][Full Text] [Related]
39. [Wnt signaling and bone metabolic diseases.].
Yamauchi M; Sugimoto T
Clin Calcium; 2019; 29(3):329-336. PubMed ID: 30814378
[TBL] [Abstract][Full Text] [Related]
40. Sclerostin Concentration and Bone Biomarker Trends in Patients with Spinal Cord Injury: A Prospective Study.
Lee JH; Cho JH; Lee DG
Healthcare (Basel); 2022 May; 10(6):. PubMed ID: 35742035
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
